Analyst consensus rating
AtriCure Analyst Rating: Buy
ATRC is rated Buy by 9 analysts with a $49.56 target. As of 2026-08-31.
Direct answer
AtriCure's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $49.56.
Forecast evidence checked August 31, 2026.
Get free AtriCure email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $48.54
- Average price target
- $49.56
- High price target
- $60.00
- Low price target
- $36.00
- Low target gap
- -25.8%
- Target upside
- +2.1%
- High target gap
- +23.6%
- Target range width
- 49.4%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AtriCure?
AtriCure has a verified Buy consensus. The same dataset has an average price target of $49.56.
How far are AtriCure's low and high targets from the recorded price?
The low target implies -25.8%, while the high target implies +23.6%.
How many analysts are included in AtriCure's consensus?
The verified consensus includes 9 analysts.
How is AtriCure's target upside or downside calculated?
The average target of $49.56 is divided by the recorded price of $48.54, then one is subtracted to produce +2.1%. This does not guarantee a future return.
When was AtriCure's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.